Evidence map›Paper›PMID 32350662›Full record

ArticleEuropean radiology2020

MRI-directed high-frequency (29MhZ) TRUS-guided biopsies: initial results of a single-center study.

François Cornud, Arnaud Lefevre, Thierry Flam, Olivier Dumonceau, Marc Galiano, Philippe Soyer, Philippe Camparo, Matthias Barral

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06579911 (Combining High-frequency Micro-ultrasound Target Biopsy and Multiparametric MRI Target Biopsy - Does it Increase the Detection Rate of Clinically Significant Prostate Cancer? A Prospective, Interventional, Single Centre, Randomized Controlled Trial), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06579911 narecruitingnot on this mapstarted 2023, after this paper: background citation

Combining High-frequency Micro-ultrasound Target Biopsy and Multiparametric MRI Target Biopsy - Does it Increase the Detection Rate of Clinically Significant Prostate Cancer? A Prospective, Interventional, Single Centre, Randomized Controlled Trial

TypeinterventionalSponsorSalzburger LandesklinikenRan2023 to 2028Enrolled400ConditionsProstatic Neoplasm of Uncertain BehaviorArmsHigh-frequency micro-ultrasound target biopsy, conventional Multiparametric MRT target biopsy
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

François CornudDepartment of Radiology, Clinique de l'Alma, Paris, France. francois.cornud@imagerietourville.com.
Arnaud LefevreDepartment of Radiology, Clinique de l'Alma, Paris, France.
Thierry FlamDepartment of Urology, Clinique St Jean de Dieu, Paris, France.
Olivier DumonceauDepartment of Urology, Clinique Turin, Paris, France.
Marc GalianoDepartment of Urology, Clinique de l'Alma, Paris, France.
Philippe SoyerDepartment of Radiology, Hôpital Cochin, Assistance Publique Hôpitaux Paris, AP-HP, Paris, France.
Philippe CamparoCentre de Pathologie, Amiens, France.
Matthias BarralDepartment of Radiology, Hôpital Cochin, Assistance Publique Hôpitaux Paris, AP-HP, Paris, France.
Alma Consulting Group · FRHôpital Cochin · FRCentre Hospitalier Universitaire Amiens-Picardie · FRClinique Ambroise Paré · FRClinique Saint Jean Languedoc · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the ability of high-frequency (29 MHz) transrectal micro-ultrasound (microUS) as a second-look examination after biparametric MRI (bp-MRI) and to reidentify focal lesions seen on diagnostic MRI and to detect new ones

methodsA total of 118 consecutive men (mean age, 66 ± 13 [SD] years; range, 49-93 years) with a mean prostate-specific antigen level of 11 ± 19 (SD) ng/mL (range, 2-200 ng/mL) and at least one focal lesion (MRI+) with a score > 2 on bp-MRI were included. Of these, 79/118 (66.9%) were biopsy-naïve and 102/118 (86.5%) had non-suspicious rectal examination. All patients had MRI-directed microUS-guided biopsy using a 29-MHz transducer. All lesions visible on micro-ultrasound (microUS+) were targeted without image fusion, which was only used for MRI+/microUS- lesions. Significant prostate cancer (sPCa) was defined by a Gleason score ≥ 7 or a maximum cancer core length > 3 mm.

resultsA total of 144 focal prostatic lesions were analyzed, including 114 (114/144, 79.2%) MRI+/microUS+ lesions, 13 MRI+/microUS- lesions (13/144, 9%), and 17 MRI-/microUS+ lesions (17/144, 11.8%). Significant PCa was detected in 70 MRI+/microUS+ lesions (70/114, 61.4%), in no MRI+/microUS- lesion (0/13, 0%), and in 4 MRI-/microUS+ lesions (4/17, 23.5%). The sensitivity and specificity of microUS on a per-patient and a per-lesion basis were 100% (95% CI, 84.9-100%) and 22.8% (95% CI, 12.5-35.8%) and 100% (95% CI, 85.1-100%) and 22.6% (95% CI, 12.3-36.2%), respectively.

conclusionMicroUS, as a second-look examination, may show promise to localize targets detected on bp-MRI. KEY POINTS: • Used as a second-look examination, microUS-guided biopsies have a 100% detection rate of sCa originating in the PZ or lower third of the TZ, without microUS-MRI image fusion. • MicroUS results may provide additional information about lesions visible on MRI. • MicroUS may provide the ability to detect small PZ lesions undetected by bp-MRI.

Indexed as

AgedAged, 80 and overBiomarkers, TumorEndosonographyHumansImage-Guided BiopsyKallikreinsMagnetic Resonance Imaging, InterventionalMaleMiddle AgedNeoplasm GradingProstate-Specific AntigenProstatic NeoplasmsUrethraBiomarkers, TumorKallikreinsKLK3 protein, humanProstate-Specific AntigenBiopsyMagnetic resonance imagingProstatic neoplasmsUltrasonography

Identifiers

PMID32350662
OpenAlexW3022544115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.